Patents by Inventor Mark Munson

Mark Munson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230159438
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 25, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Helen Yeoman, Martin Smrcina, Ronghua Li, Ryan Hartung, William Wire, Bertrand Vivet, Nina Ma
  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230159439
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 25, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Joseph Kim, Martin Smrcina, Nina Ma, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet
  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230147360
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 11, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Martin Smrcina, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet, Andrew Scholte
  • 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
    Publication number: 20230137585
    Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: May 11, 2022
    Publication date: May 4, 2023
    Inventors: Zhongli Gao, Gregory Hurlbut, Mark Munson, Junkai Liao
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20220332687
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 20, 2022
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • UDP glycosyltransferase inhibitors and methods of use
    Patent number: 11098056
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 24, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Sungtaek Lim, Robert H. Barker, Jr., Mary A. Cromwell, Elina Makino, Bradford Hirth, John Jiang, Sachin Maniar, Mark Munson, Yong-Mi Choi, Sukanthini Thurairatnam, Kwon Yon Musick, James Pribish, Michael Angelastro
  • Heteroaryl compounds and uses thereof
    Patent number: 10774052
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: September 15, 2020
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
    Patent number: 10618902
    Abstract: The present invention provides substituted pyrido[2,3-d]pyrimidine compounds useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: April 14, 2020
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
    Publication number: 20200102324
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Application
    Filed: October 1, 2019
    Publication date: April 2, 2020
    Inventors: Sungtaek LIM, Robert H. BARKER, JR., Mary A. CROMWELL, Elina MAKINO, Bradford HIRTH, John JIANG, Sachin MANIAR, Mark MUNSON, Yong-Mi CHOI, Sukanthini THURAIRATNAM, Kwon Yon MUSICK, James PRIBISH, Michael ANGELASTRO
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190375719
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 23, 2019
    Publication date: December 12, 2019
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20190218220
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
    Type: Application
    Filed: August 28, 2018
    Publication date: July 18, 2019
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • Heteroaryl compounds and uses thereof
    Patent number: 10189794
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 29, 2019
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
    Patent number: 10065966
    Abstract: The present invention provides compounds of formula I-h: useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: September 4, 2018
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180022713
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 25, 2018
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20170267685
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • Heteroaryl compounds and uses thereof
    Patent number: 9695132
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: July 4, 2017
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
    Patent number: 9663524
    Abstract: The present invention provides compounds of formula I-h: useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 30, 2017
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
  • HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160221966
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 20, 2016
    Publication date: August 4, 2016
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • AKT PROTEIN KINASE INHIBITORS
    Publication number: 20160152576
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2014
    Publication date: June 2, 2016
    Applicant: Array BioPharma, Inc.
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicolas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • Heteroaryl compounds and uses thereof
    Patent number: 9321786
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 26, 2016
    Assignees: Celgene Avilomics Research, Inc., Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson